| Ytd | 81.49% | |
| 1y | 55.35% |
| Open | 7.62 | Prev Close | 7.62 | Low | 7.62 | High | 7.90 | Mkt Cap | 97.75M |
| Vol | 2.01K | Avg Vol | 419.62K | EPS | -3.95 | P/E | -1.93 | Forward P/E | -0.66 |
| Beta | 1.25 | Short Ratio | 2.42 | Inst. Own | 44.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.42 | 200-d Avg | 5.97 | 1yr Est | 33.60 |
DTIL News
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being high
Also in its updated corporate deck, the Company announced activation of a second clinical site at Wa
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Cons
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Tra
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (DTIL) reached a significant support level, and could be a good pick for
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
During Monday's trading, 1214 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report